Comparative Pharmacology
Head-to-head clinical analysis: FLUORINE F 18 versus MPI STANNOUS DIPHOSPHONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORINE F 18 versus MPI STANNOUS DIPHOSPHONATE.
FLUORINE F-18 vs MPI STANNOUS DIPHOSPHONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorine-18 decays by positron emission, and the emitted positron annihilates with an electron to produce two 511 keV gamma photons. When incorporated into radiopharmaceuticals such as fludeoxyglucose F-18, it accumulates in metabolically active tissues, enabling PET imaging.
Stannous diphosphonate is a radiopharmaceutical agent that forms a complex with technetium-99m; it localizes to areas of increased bone turnover by chemisorption to hydroxyapatite crystals, thereby enabling bone scintigraphy.
2-10 mCi (74-370 MBq) intravenous bolus, single administration for PET imaging.
Adult: 1-4 mg administered intravenously, single dose for bone scintigraphy.
None Documented
None Documented
Physiological half-life is 109.7 minutes (1.83 hours) for fluorine-18 decay by positron emission, with a physical half-life of 109.7 minutes. The biological half-life is dependent on the radiolabeled compound; for [18F]FDG, the effective half-life is approximately 3-4 hours.
Terminal elimination half-life: Approximately 2.5 hours for the diphosphonate component; the stannous ion is cleared more slowly. Clinically, this allows rapid bone uptake and background clearance for imaging within 2–4 hours post-injection.
Primarily renal; approximately 95% of administered activity is excreted in urine within 6 hours post-injection. Less than 5% is excreted in feces.
Renal: >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal: Minimal (<2%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical